The US health authority FDA examines the approval of the Bavarian active ingredient Finerenon for the treatment of adult patients with heart failure in an accelerated procedure.
This was announced by the company in Berlin. Approval usually shortens from 10 to 6 months.
An extended indication for the treatment of heart failure with a left ventricular ejection fraction of at least 40 percent for the USA could be granted in the third quarter, said Bayer.
The medication led under the brand name Kerendia has so far been used in more than 90 countries for the treatment of adult patients with chronic kidney disease in conjunction with type 2 diabetes. The drug is considered a possible blockbuster.
The Bayer share temporarily notes 1.25 percent higher at 23.58 euros via Xetra.
Dow Jones
Selected leverage products on Bayer
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Bayer
The lever must be between 2 and 20
Advertising